tbuckley/cabot-search huggingface dataset:
Responsiveness to Resistance-Based Multimodal Exercise Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy
Authors: Dennis R. Taaffe, Robert U. Newton, Nigel Spry, David J. Joseph, Daniel A. Galvão
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Androgen deprivation therapy (ADT) in the management of prostate cancer (PCa) results in an array of adverse effects, and exercise is one strategy to counter treatment-related musculoskeletal toxicities. This study assessed the prevalence of exercise responsiveness in men with PCa undergoing ADT in terms of body composition, muscle strength, and physical function. Methods: Prospective analyses were performed in 152 men (aged 43–90 years) with PCa receiving ADT who were engaged in resistance exercise combined with aerobic or impact training for 3 to 6 months. Whole-body lean mass and fat mass (FM), trunk FM, and appendicular skeletal muscle were assessed with dual x-ray absorptiometry; upper and lower body muscle strength were assessed with the one-repetition maximum; and physical function was assessed with a battery of tests (6-m usual, fast, and backward walk; 400-m walk; repeated chair rise; stair climb). Results: Significant improvements were seen ( P &lt;.01) in lean mass (0.4±1.4 kg [range, −2.8 to +4.1 kg]), appendicular skeletal muscle (0.2±0.8 kg [range, −1.9 to +1.9 kg]), and all measures of muscle strength (chest press, 2.9±5.8 kg [range, −12.5 to +37.5 kg]; leg press, 29.2±27.6 kg [range, −50.0 to +140.0 kg]) and physical function (from −0.1±0.5 s [range, +1.3 to −2.1 s] for the 6-m walk; to −8.6±15.2 s [range, +25.2 to −69.7 s] for the 400-m walk). An increase in FM was also noted (0.6±1.8 kg [range, −3.6 to +7.3 kg]; P &lt;.01). A total of 21 men did not exhibit a favorable response in at least one body composition component, 10 did not experience improved muscle strength, and 2 did not have improved physical function. However, all patients responded in at least one of the areas, and 120 (79%) favorably responded in all 3 areas. Conclusions: Despite considerable heterogeneity, most men with PCa receiving ADT responded to resistance-based multimodal exercise, and therefore our findings indicate that this form of exercise can be confidently prescribed to produce beneficial effects during active treatment.
Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study
Authors: Emanuele Zucca, Annarita Conconi, Giovanni Martinelli, Maurizio Martelli, Catherine Thieblemont, Peter W Johnson, Armando Lopez-Guillermo, Reda Bouabdallah, Alessandra Tucci, Umberto Vitolo, Bertrand Coiffier, Liliana Devizzi, Fabrice Jardin, Catherine Sebban, Graziella Pinotti, Franck Morschhauser, Ruth Pettengell, Andre Bosly, Emili Montserrat, Monica Bellei, Stefano A. Pileri, Christiane Copie-Bergman, Elias Campo, Andrew Jack, Luca Mazzucchelli, Franco Cavalli
Journal: Blood (2010)
Lenalidomide (Revlimid), Bortezomib (Velcade) and Dexamethasone (RVD) for Heavily Pretreated Relapsed or Refractory Multiple Myeloma
Authors: Victor H Jimenez-Zepeda, Donna E. Reece, Suzanne Trudel, Christine Chen, Vishal Kukreti
Journal: Blood (2011)
Early-Polycythemia Vera (e-PV) with Thrombocytosis: Clinical Characteristics, Morphological Features and JAK2V617F Mutational Status Contributing to the Differential Diagnosis with Essential Thrombocythemia.
Authors: Alessandra Iurlo, Umberto Gianelli, Alessia Moro, Paola Bianchi, Elisa Fermo, Claudia Vener, Federica Savi, Radaelli Franca, Silvano Bosari, Alberto Zanella
Journal: Blood (2006)
The Influence of Social and Economic Factors on Heart Disease
Authors: Edward P. Havranek
Journal: JAMA Cardiology (2019)

Stephen Y. Wang, MPH; Andy S. L. Tan, MD, PhD, MPH, MBA; Brian Claggett, PhD; Alvin Chandra, MD; Sameed Ahmed M. Khatana, MD; Pamela L. Lutsey, PhD, MPH; Anna Kucharska-Newton, PhD; Silvia Koton, PhD; Scott D. Solomon, MD; Ichiro Kawachi, MD, PhD
The Osteoclast Targeting Therapy In Bone Metastasis For a Mouse Model Of Adult T Cell Leukemia
Authors: Takuo Mizukami, Kazuya Takizawa, Jumpei Yamazaki, Wakako Kuribayashi, Madoka Kuramitsu, Ryuji Hiramatsu, William W Hall, Hideki Hasegawa, Kazunari Yamaguchi, Isao Hamaguchi
Journal: Blood (2013)
Biomarker Correlates of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Authors: Jasper Tromp, Camilla Hage, Wouter Ouwerkerk, Sandra Sanders-van Wijk, Sara Svedlund, Antti Saraste, Ulrika Ljung Faxén, Maria Lagerstrom Fermer, Li-ming Gan, Lars H. Lund, Sanjiv J. Shah, Carolyn S.P. Lam
Journal: Circulation (2019)
Azacitidine (AZA) Combination Therapy with Low-Dose AraC Is Well Tolerated and Highly Effective for MDS with Overt Leukemia
Authors: Manabu Hirai, Mizuki Aimoto, Atsushi Inoue, Mitsuharu Hashimura, Erina Sakamoto, Hirohisa Nakamae, Masayuki Hino
Journal: Blood (2014)
The TLR4 polymorphism predicts the response of breast cancer patients to anthracyclins
Authors: F. Ghiringhelli, L. Apetoh, A. Tesniere, F. Andre, R. Lidereau, S. Delaloge, A. Chompret, G. Kroemer, L. Zitvogel
Journal: Journal of Clinical Oncology (2007)

10612 Background: Conventional anticancer therapy mainly relies upon chemotherapy which supposedly directly eliminates tumor cells. However, we showed in mice that chemotherapy-induced tumor cell death markedly enhanced T-cell mediated tumor rejection, suggesting a role of innate immune receptors in the response to anthracyclins. Moreover, anthracyclins are less effective in athymic nude or Toll like receptor-4 (TLR4) deficient mice (Obeid et al. Nat. Med. 2006). A single nucleotide polymorphism (SNP) in TLR4 (896A/G, Asp299Gly) affecting the extracellular domain of TLR4 is associated with reduced endotoxin responses in humans. We addressed whether the TLR4 SNP could affect the response to anthracyclins in breast cancer patients. Methods: We included 280 patients from three cancer centers bearing non-metastatic breast cancer presenting with lymph node involvement and treated with anthracyclin-based regimen after local surgery. TLR4 genotyping performed on leukocytes (PCR based on exonuclease degradation of dual labelled allele-specific oligos) and statistical analyses were performed in a blinded fashion. Results: The frequency of Asp299Gly (heterozygote) and Gly299Gly (homozygote) TLR4 germline polymorphisms was 17.1 and 0.7 % respectively. Patients that exhibited a mutated TLR4 allele did not differ from patients displaying the normal TLR4 allele for all classical prognostic factors (age, pathological tumor size, lymph node involvement, tumor grade, hormone receptors, and median follow up, p&gt;0.05). However, the frequency of metastases was statistically higher in the mutated TLR4 group five years after surgery (40% versus 26.5% in non mutated patients, p &lt;0.05, RR: 1.7, 95% CI [1.2–3.6]). Moreover, the Kaplan Meier estimate of metastasis-free survival indicated an overall significantly lower percentage of metastases-free patients in the mutated TLR4 group (Log rank test, p = 0.03). Conclusions: It is the first demonstration of the role of innate immunity and TLR4 in the response to anthracyclins in localized breast cancer. No significant financial relationships to disclose.
The Growth Differentiation Factor-15 Levels Are Increased in Patients with Compound Heterozygous Sickle Cell and Beta-Thalassemia, Correlate with Hepcidin-25/Ferritin Molar Ratio and with Markers of Hemolysis, Endothelial Dysfunction and Angiogenesis
Authors: Ioannis Papassotiriou, Katerina Larrisi, Alexandra Margeli, Dimitrios Christoulas, Maria Dimopoulou, Vaughn Ostland, Christos Poziopoulos, Mark Westerman, Marianna Politou, Ersi Voskaridou, Evangelos Terpos
Journal: Blood (2016)
RNA-Sequencing Unveils Cryptic Fusions in Patients with Acute Myeloid Leukemia
Authors: Fabiana Ostronoff, Matthew Fitzgibbon, Martin McIntosh, Rhonda E. Ries, Alan S. Gamis, Todd A. Alonzo, Frederick R. Appelbaum, Derek L. Stirewalt, Soheil Meshinchi
Journal: Blood (2012)
Transfection of NK Cells with mRNA or Lentivirus Expressing Chimeric Antigen Receptors Results in Highly Efficient Killing of Lymphoid Malignancies and Compares Favorably with Monoclonal Antibody-Directed ADCC.
Authors: Laurent Boissel, Monica Betancur, Richard A. Van Etten, Hans-Georg Klingemann
Journal: Blood (2009)
Addressing the Challenge of Polypharmacy
Authors: Alpana Mair, Martin Wilson, Tobias Dreischulte
Journal: The Annual Review of Pharmacology and Toxicology (2019)

Polypharmacy describes the concomitant use of multiple medicines and represents a growing global challenge attributable to aging populations with an increasing prevalence of multimorbidity. Polypharmacy can be appropriate but is problematic when the increased risk of harm from interactions between drugs or between drugs and diseases or the burden of administering and monitoring medicines outweighs plausible benefits. Polypharmacy has a substantial economic impact in service demand and hospitalization as well as a detrimental impact on patients' quality of life. Apart from causing avoidable harm, polypharmacy can also lead to therapeutic failure, with up to 50% of patients who take four or more medications not taking them as prescribed. Guidance is needed to support patients and clinicians in defining and achieving realistic goals of drug treatment, and system change is necessary to aid implementation. This article outlines lessons from two programs that aim to address these challenges: the Scottish polypharmacy guidance on realistic prescribing and the European Union SIMPATHY project.
Sustained Antibody Responses Depend on CD28 Function in Bone Marrow Resident Plasma Cells
Authors: Cheryl H Rozanski, Lindzy F Dodson, Ramon Arens, Louise M Carlson, Lisa M Russell, Jayakumar R Nair, Asher Chanan-Khan, Lee Ann Garrett-Sinha, Jonathan M Green, Stephen P Schoenberger, Lawrence H. Boise, Kelvin P Lee
Journal: Blood (2011)
White Matter Connectivity Abnormalities in Prediabetes and Type 2 Diabetes: The Maastricht Study
Authors: Laura W. Vergoossen, Miranda T. Schram, Joost J. de Jong, Coen D. Stehouwer, Nicolaas C. Schaper, Ronald M. Henry, Carla J. van der Kallen, Pieter C. Dagnelie, Martin P. van Boxtel, Simone J. Eussen, Walter H. Backes, Jacobus F. Jansen
Journal: Diabetes Care (2019)

OBJECTIVE Prediabetes and type 2 diabetes are associated with structural brain abnormalities, often observed in cognitive disorders. Besides visible lesions, (pre)diabetes might also be associated with alterations of the intrinsic organization of the white matter. In this population-based cohort study, the association of prediabetes and type 2 diabetes with white matter network organization was assessed. RESEARCH DESIGN AND METHODS In the Maastricht Study, a type 2 diabetes–enriched population-based cohort study (1,361 subjects with normal glucose metabolism, 348 with prediabetes, and 510 with type 2 diabetes assessed by oral glucose tolerance test; 52% men; aged 59 ± 8 years), 3 Tesla structural and diffusion MRI was performed. Whole-brain white matter tractography was used to assess the number of connections (node degree) between 94 brain regions and the topology (graph measures). Multivariable linear regression analyses were used to investigate the associations of glucose metabolism status with network measures. Associations were adjusted for age, sex, education, and cardiovascular risk factors. RESULTS Prediabetes and type 2 diabetes were associated with lower node degree after full adjustment (standardized [st]βPrediabetes = −0.055 [95% CI −0.172, 0.062], stβType2diabetes = −0.256 [−0.379, −0.133], Ptrend &amp;lt; 0.001). Prediabetes was associated with lower local efficiency (stβ = −0.084 [95% CI −0.159, −0.008], P = 0.033) and lower clustering coefficient (stβ = −0.097 [95% CI −0.189, −0.005], P = 0.049), whereas type 2 diabetes was not. Type 2 diabetes was associated with higher communicability (stβ = 0.148 [95% CI 0.042, 0.253], P = 0.008). CONCLUSIONS These findings indicate that prediabetes and type 2 diabetes are associated with fewer white matter connections and weaker organization of white matter networks. Type 2 diabetes was associated with higher communicability, which was not yet observed in prediabetes and may reflect the use of alternative white matter connections.
Adoptive Transfer of Hexon-Specific T-Cells as a Treatment of Adenovirus Reactivation Following Allogeneic Stem Cell Transplantation.
Authors: Kathrin Opherk, Friedhelm R Schuster, Wolfgang Andreas Bethge, Peter Bader, Johann Greil, Gernot Stuhler, Michael H Albert, Martin G. Sauer, Rupert Handgretinger, Peter Lang, Tobias Feuchtinger
Journal: Blood (2009)
Abstract 14950: Meta-analysis of Oral Anticoagulants With Dual vs Single Antiplatelet Therapy in Patients After Coronary Intervention
Authors: Alexandros Briasoulis, Shikha Sharma, Sagar Mallikethi-Reddy, Nikolaos Papageorgiou, Mohan Palla, Dimitris Tousoulis
Journal: Circulation (2015)

Background: Combined use of dual antiplatelet therapy with oral anticoagulation (OAC) is required in some patients with after coronary artery stenting or acute coronary syndrome (ACS). Methods: We performed a meta-analysis of the comparative effects of triple antithrombotic therapy (TT) vs OAC with single antiplatelet therapy (DT) on all-cause mortality, stroke, cardiovascular death, myocardial infarction, target vessel revascularization and major bleeding. We conducted an EMBASE and MEDLINE search for prospective controlled trials and cohort studies of patients requiring anticoagulation after coronary stenting. Results: We identified 3 prospective controlled studies and 5 cohort studies, which compared TT vs dual therapy (DT). We identified 4 prospective controlled and 6 cohort studies with 4564 patients on TT and 1848 on DT with an average follow up duration of 10.1 months. TT is associated with similar rates of all-cause mortality, stroke and major bleeding but significantly lower rates of myocardial infarction compared to DT (mainly OAC plus clopidogrel). Conclusion: Triple antithrombotic therapy is associated with similar mortality and bleeding rates but less myocardial infarctions compared with OAC and single antiplatelet therapy.
Intense Immunochemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909. A Preliminary Report.
Authors: Lloyd Damon, Donna Niedzwiecki, Jeff Johnson, Bruce Cheson, David Hurd, Nancy Barlett, Michael Kelly, Charles Linker, George Canellos
Journal: Blood (2004)
An Open-Label, Multicenter, 2-Arm, Dose-Finding, Phase 1b Study of the Combination of Ruxolitinib and Buparlisib (BKM120) in Patients with Myelofibrosis: Results from HARMONY Study
Authors: Simon T Durrant, Arnon Nagler, Alessandro M Vannucchi, David Lavie, Charles Chuah, Francesco Passamonti, Heinz Gisslinger, Philipp le Coutre, Prashanth Gopalakrishna, Bruyère Mahuzier, Shuyuan Mo, Joaquin Martinez-Lopez
Journal: Blood (2015)
Extracorporeal Adsorption Following Infusion of Radiolabeled Anti-CD20 Antibody Clears Unbound Radioimmunoconjugate from the Circulation and Reduces Radiation Exposure of Normal Organs in the Nonhuman Primate.
Authors: Damian J. Green, Eneida R. Nemecek, Nathan Hedin, Anastasia Pantelias, Yukang Lin, John M. Pagel, Darrell R. Fisher, Don K. Hamlin, D. Scott Wilbur, Ajay Gopal, Rune Nilsson, Bengt E.B. Sandberg, Oliver W. Press
Journal: Blood (2006)
Mechanism for the ectopic expression of coagulation factor VII in non-hepatic cancer cells: The canonical transcription factors Sp1 and HNF-4 are not involved, but the same promoter region is working with another transcription factor.
Authors: Shiro Koizume, Naho Yokota, Etsuko Miyagi, Fumiki Hirahara, Yoshiyasu Nakamura, Eiju Tsuchiya, Yohei Miyagi
Journal: Cancer Research (2007)

2902  Blood coagulation factor VII (fVII) is physiologically synthesized in the liver and released into the blood. Binding of fVII to tissue factor (TF) at sites of vascular injury triggers coagulation and hemostasis. TF/fVIIa complex formation on the surface of cancer cells plays important roles in cancer biology, including cancer cell migration and invasion, cell survival and angiogenesis. We have recently reported that some non-hepatic cancer cell lines constitutively express fVII resulting in coagulation activity on the cell surface, and that ectopic fVII expression enhances motility and invasion of a breast cancer cell MDA-MB 453 (Koizume et al., Cancer Res 2006;66:9453-60). Furthermore, the FVII gene expression was found to be inducible under hypoxia, a proinvasive cellular environment, with binding of hypoxia-inducible factor-2α (HIF-2α) to the FVII gene promoter. To elucidate mechanism of the ectopic fVII expression in non-hepatic cancer cells, we tested whether the canonical transcription factors responsible for the FVII expression in hepatocytes (Sp1 and hepatocyte nuclear factor HNF-4) bind to the FVII gene promoter by chromatin immunoprecipitation (ChIP) analysis. As expected, we found that both Sp1 and HNF-4 bind to the promoter region in a hepatic cancer cell HepG2. However, we failed to detect binding of HNF-4 to the typical promoter in a breast cancer cell YMB-1. Real-time RT-PCR analysis showed that expression level of fVII mRNA in this cell is comparable to that of HepG2 cell. We unexpectedly found that ubiquitous transcription factor Sp1 does not bind to the promoter region too. ChIP also revealed that histone H4 at the same locus is hyperacetylated in YMB-1 cells, indicating that the promoter is transcriptionally active in the absence of Sp1 and HNF-4 bindings. Next, We explored cis-acting elements responsible for the ectopic FVII gene expression in YMB-1 cells by luciferase-reporter assay. The construct lacking Sp1 binding site (5â\#8364;™-CCCCTCCCCC-3â\#8364;™) had no promoter activity as in case of experiments using HepG2 cell, implicating that other transcription factor(s) recognizing the same Sp1 consensus binding site may play a crucial role in the ectopic FVII gene expression. We will further present binding characteristics of the putative transcription factor to the cis-acting element in breast cancer cells.
Analysis of Copy Number Abnormalities of 86 Acute Lymphoblastic Leukemia Cell Lines Based on the Genetic Subtypes
Authors: Chihiro Tomoyasu, Toshihiko Imamura, Mio Yano, Daisuke Asai, Meixian Huang, Hiroaki Goto, Akira Shimada, Takeshi Inukai, Kanji Sugita, Hajime Hosoi
Journal: Blood (2015)
Chimerism Kinetics of Unfractionated Bone Marrow In the First Year After Allogeneic Hematopoietic Cell Transplantation Is Predictive of Relapse In Patients with AML and MDS.
Authors: Apostolia Papalexandri, Chryssa Apostolou, Georgia Voutiadou, Tasoula Touloumenidou, Ioannis Zorbas, Ioannis Batsis, Christos Smias, Evangelia Stalika, Angeliki Paleta, Ioanna Sakellari, Achilles Anagnostopoulos
Journal: Blood (2010)
Prolonged Transportation Time Of Haemopoietic Progenitor Cells Does Not Impact Upon Engraftment Or Overall Survival Following Allogeneic Voluntary Unrelated Donor Transplantation
Authors: Cheryl J Hutchins, Jason P Butler, Angela McLean, Judith Y Cummings, Geoff R Hill, James A Morton, Glen A Kennedy, Simon TS Durrant
Journal: Blood (2013)
Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia
Authors: M. Fürstenau, J. Bahlo, A. M. Fink, E. Lange, P. Dreger, M. Dreyling, G. Hess, M. Ritgen, M. Kneba, H. Döhner, S. Stilgenbauer, C. M. Wendtner, V. Goede, K. Fischer, S. Böttcher, M. Hallek, B. Eichhorst
Journal: Leukemia (2019)
New Fissure-Attached Nodules in Lung Cancer Screening: A Brief Report From The NELSON Study
Authors: Daiwei Han, Marjolein A. Heuvelmans, Carlijn M. van der Aalst, Lisa H. van Smoorenburg, Monique D. Dorrius, Mieneke Rook, Kristiaan Nackaerts, Joan E. Walter, Harry J.M. Groen, Rozemarijn Vliegenthart, Harry J. de Koning, Matthijs Oudkerk
Journal: Journal of Thoracic Oncology (2019)
Is There a Role for Autologous Stem-Cell Transplantation (ASCT) in Peripheral T-Cell Lymphoma (PTCL)? Final Results of a Prospective Phase II Study from the GELCAB.
Authors: Santiago Mercadal, Armando Lopez-Guillermo, Javier Briones, Blanca Xicoy, Carme Pedro, Lourdes Escoda, Cristina Estany, Mireia Camos, Josep-Maria Ribera, Rodrigo Martino, Lluis Colomo, Emili Montserrat
Journal: Blood (2006)
Higher Percentage of CD34+CD38− Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predict Unsustained Complete Remission in AML
Authors: Adriana Plesa, Mohamed Elhamri, Gilles Clapisson, Eve Mattei, Sophie Gazzo, Olivier Hequet, Mauricette Michallet, Charles Dumontet, Xavier Thomas
Journal: Blood (2012)
Clinical Trials Underestimate Age of Chronic Myeloid Leukemia (CML) Patients: Epidemiological Study in a Representative Area in Germany.
Authors: M. Rohrbacher, U. Berger, A. Hochhaus, G. Metzgeroth, K. Adam, T. Lahaye, S. Saussele, J. Hasford, H. Heimpel, Rüdiger Hehlmann
Journal: Blood (2007)
The Role of RANKL/Osteoprotegerin and Wnt Signaling Pathways in the Development of Osteoporosis in Patients with Hemophilia
Authors: Panagiotis Anagnostis, Sofia Vakalopoulou, Dimitrios Christoulas, Spyridon Karras, Athanasios Papatheodorou, Eirini Katodritou, Panagiotis Kokkoris, Vasilia Garipidou, Evangelos Terpos
Journal: Blood (2015)
Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer
Authors: Yohei Kubota, Akihito Kawazoe, Yoshiaki Nakamura, Akinori Sasaki, Saori Mishima, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino, Takeshi Kuwata, Kohei Shitara
Journal: Annals of Oncology (2019)
Risk Factors and Prognosis of Hemorrhagic Cystitis after Allogeneic Stem Cell Transplantation: Retrospective Analysis in a Single Institution
Authors: Yasuyuki Arai, Takeshi Maeda, Hiroyuki Sugiura, Hiroyuki Matsui, Tomoko Moriwake, Tomoyasu Jo, Tomoaki Ueda, Kazuya Okada, Takahito Kawata, Tatsuhito Oonishi, Chisato Mizutani, Fumio Matsuyama, Yasunori Ueda
Journal: Blood (2010)
Gene Expression Profiling of Age-Related Epstein-Barr Virus (EBV)-Associated B-Cell Lymphoproliferative Disorder Uncovers Alterations in Immune and Inflammatory Genes: Possible Implications for Pathogenesis,
Authors: Harumi Kato, Kazuhito Yamamoto, Kennosuke Karube, Miyuki Katayama, Shinobu Tsuzuki, Yasushi Yatabe, Jun Takizawa, Koichi Ohshima, Shigeo Nakamura, Yasuo Morishima, Masao Seto
Journal: Blood (2011)
The Combination of High Expression of CD68-Positive Tumor-Associated Macrophages and PET2-Positivity Predicts Unfavorable Outcome in Patients with Classical Hodgkin Lymphoma Treated in the Lysa AHL2011 Study
Authors: Alexandra Traverse-Glehen, Diane Damotte, Peggy Dartigues, Laurent Martin, Marie Parrens, Hervé Guesquieres, Clementine Sarkozy, Bénédicte Deau, Reda Bouabdallah, Sylvain Garciaz, Michel Meignan, Véronique Edeline, Salim Kanoun, Alina Berriolo-Riedinger, Pauline Brice, Cedric Rossi, Aspasia Stamatoullas, Anne Sophie Veillard, Marc Andre, Olivier Casasnovas
Journal: Blood (2016)
MERIT Study – “Multicenter Evaluation of Patient- and Lesion-Specific Prognostic Factors for RadioImmunoTherapy with 90yttrium-Labeled Anti-CD20 in Follicular Non-Hodgkin's lymphoma”.
Authors: Aleksandar Grgic, Ursula Nestle, Elena Ballek, Klemens Scheidhauer, Cornelia Puskas, Jochem Koenig, Karin Hohloch, Joerg Schubert, Lorenz H. Truemper, Carl-Martin Kirsch
Journal: Blood (2009)
Fc-Engineered RANK-Fc Fusion Proteins for Neutralization of Soluble RANKL and Induction of Antibody-Dependent Cellular Cytotoxicity (ADCC) Against Multiple Myeloma
Authors: Benjamin J Schmiedel, Carolin Scheible, Tina Baessler, Constantin M Wende, Stefan Wirths, Miyuki Azuma, Pascal Schneider, Ludger Grosse-Hovest, Lothar Kanz, Helmut R Salih
Journal: Blood (2010)
Acalabrutinib Monotherapy in Patients with Richter Transformation from the Phase 1/2 ACE-CL-001 Clinical Study
Authors: Peter Hillmen, Anna Schuh, Toby A. Eyre, John M. Pagel, Jennifer R. Brown, Paolo Ghia, John N. Allan, William Wierda, Ahmed Hamdy, Jane Huang, Raquel Izumi, Priti Patel, Min Hui Wang, John C. Byrd
Journal: Blood (2016)